Arca Biopharma (ABIO) Stock Heads Up: Here’s What You Need To Know

ARCA Biopharma ABIO Stock News

Arca Biopharma Inc (NASDAQ: ABIO) is making a run for the top in the premarket hours this morning. However, if you’re looking for press releases or SEC filings, you’re not going to find anything. The company hasn’t issued anything of substance this morning. So, what’s the deal?

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Why ABIO Stock Is Flying

While Arca Biopoharma hasn’t issued any news as of late, there’s good reason to be excited about the stock. The company is currently working on a treatment known as AB201 as a potential treatment option for COVID-19.

It is expected that some time before the end of the month, the company will submit its Investigational New Drug Application to the FDA in order to move forward with a Phase IIb clinical trial.

If all goes well, the ABIO Phase IIb trial will start as early as next quarter. That’s exciting.

The fact of the matter is that while vaccines seem to be on the way, COVID-19 is likely to be a long-term issue. After all, this isn’t the only coronavirus that human kind has seen. In fact, coronavirus strains are the reason we get the common cold.

Importantly, the common cold has shown us what to expect. Even if vaccines are effective, immune effects from the vaccine, or vaccines, will not last forever. Not to mention, there’s a large population of consumers that refuse to take vaccinations.

As a result, there’s good reason to expect that COVID-19 is going to be here fore the long-haul. With a condition like this being around, there will need to be effective treatment options. Of course, if ABIO proves that its AB201 treatment is effective, it could take a large piece of this growing market moving forward.

Final Thoughts

The bottom line here is a simple one. ABIO is on the verge of submitting an IND and moving forward with a Phase IIb clinical trial in a COVID-19 treatment. Not only will the treatment come with tremendous revenue potential if approved, the fact that the company is working in COVID-19 will likely continue to increase investor awareness, further building interest.

For these reasons, ABIO is a stock that should be watched closely.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.